[go: up one dir, main page]

MX2009009200A - Tratamiento de enfermedades caracterizadas por la inflamacion. - Google Patents

Tratamiento de enfermedades caracterizadas por la inflamacion.

Info

Publication number
MX2009009200A
MX2009009200A MX2009009200A MX2009009200A MX2009009200A MX 2009009200 A MX2009009200 A MX 2009009200A MX 2009009200 A MX2009009200 A MX 2009009200A MX 2009009200 A MX2009009200 A MX 2009009200A MX 2009009200 A MX2009009200 A MX 2009009200A
Authority
MX
Mexico
Prior art keywords
treatment
inflammation
diseases characterized
methods
pathway
Prior art date
Application number
MX2009009200A
Other languages
English (en)
Inventor
Michael Kaleko
Tianci Luo
Original Assignee
Advanced Vision Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Vision Therapies Inc filed Critical Advanced Vision Therapies Inc
Publication of MX2009009200A publication Critical patent/MX2009009200A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La invención proporciona, en parte, métodos, ácidos nucleicos, vectores, proteínas y moléculas de enlace que se pueden utilizar para modular una vía tal como una vía del complemento. Estos métodos y composiciones se pueden utilizar, inter alia, para el estudio y/o tratamiento de varias condiciones o enfermedades relacionadas con una vía del complemento.
MX2009009200A 2007-03-01 2008-02-29 Tratamiento de enfermedades caracterizadas por la inflamacion. MX2009009200A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89239507P 2007-03-01 2007-03-01
US98502407P 2007-11-02 2007-11-02
PCT/US2008/055498 WO2008106644A2 (en) 2007-03-01 2008-02-29 Treatment of diseases characterized by inflammation

Publications (1)

Publication Number Publication Date
MX2009009200A true MX2009009200A (es) 2009-10-28

Family

ID=39721854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009200A MX2009009200A (es) 2007-03-01 2008-02-29 Tratamiento de enfermedades caracterizadas por la inflamacion.

Country Status (10)

Country Link
US (1) US20100120665A1 (es)
EP (1) EP2134173A4 (es)
JP (1) JP5332064B2 (es)
KR (1) KR20090122465A (es)
AU (2) AU2008221287A1 (es)
CA (1) CA2678774A1 (es)
IL (1) IL200368A0 (es)
MX (1) MX2009009200A (es)
NZ (1) NZ578873A (es)
WO (1) WO2008106644A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007210038B2 (en) 2006-01-26 2013-01-10 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
JP2011503094A (ja) 2007-11-08 2011-01-27 ジェネンテック， インコーポレイテッド 抗ｂ因子抗体およびそれらの使用
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
WO2012016162A2 (en) * 2010-07-29 2012-02-02 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
US8324182B2 (en) * 2008-02-15 2012-12-04 Tufts University Humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
EP3192874B1 (en) * 2008-06-18 2019-10-16 Oxford BioMedica (UK) Limited Virus purification
EP2894166A1 (en) 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US8778999B2 (en) 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
US11512326B2 (en) 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
CN104894129B (zh) 2009-09-11 2020-07-10 Ionis制药公司 亨廷顿表达的调节
FR2952639B1 (fr) 2009-11-16 2013-08-30 Lab Francais Du Fractionnement Procede de purification de facteur b
JP5337096B2 (ja) 2010-04-28 2013-11-06 株式会社日立製作所 動脈硬化の評価法
CA2843684A1 (en) * 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
US9244073B2 (en) 2011-02-25 2016-01-26 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
KR101949293B1 (ko) 2011-05-05 2019-02-18 웰스태트 이뮤노테라퓨틱스, 엘엘씨 보체 인자 ｂ 유사체 및 그의 용도
AU2012272706B2 (en) * 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
CN103316356B (zh) * 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
WO2013148155A1 (en) * 2012-03-26 2013-10-03 Digna Biotech Usa, Llc Compositions and methods for the treatment of dry eye disease
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
WO2014035876A1 (en) * 2012-08-27 2014-03-06 William Marsh Rice University Heat-inactivated complement factor b compositions and methods
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
JP6387391B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 眼科疾患の処置に有用な補体因子Ｂ阻害剤としての２−（１Ｈ−インドール−４−イルメチル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−６−カルボニトリル誘導体
EA034575B1 (ru) * 2013-04-18 2020-02-21 Фондацьоне Телетон Эффективная доставка больших генов посредством двойных aav векторов
SG10201906382QA (en) 2013-05-01 2019-08-27 Ionis Pharmaceuticals Inc Compositions and methods for modulating hbv and ttr expression
EP3011345B1 (en) 2013-08-07 2017-10-04 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
PE20160500A1 (es) * 2013-09-13 2016-05-21 Ionis Pharmaceuticals Inc Moduladores del factor del complemento b
JP2016535042A (ja) 2013-10-30 2016-11-10 ノバルティス アーゲー ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
WO2015138628A1 (en) * 2014-03-11 2015-09-17 University Of Florida Research Foundation, Inc. Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
SG10201809953QA (en) 2014-05-01 2018-12-28 Ionis Pharmaceuticals Inc Compositions and methods for modulating complement factor b expression
US12396889B2 (en) 2014-05-12 2025-08-26 Gholam A. Peyman Lamellar corneal autologous or homologous graft in refractive surgery
US11666777B2 (en) * 2014-05-12 2023-06-06 Gholam A. Peyman Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
WO2017202776A1 (en) * 2016-05-23 2017-11-30 Luxembourg Institute Of Health (Lih) Multifunctional heteromultimeric constructs.
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN121343934A (zh) * 2017-05-10 2026-01-16 制药五有限责任公司 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
WO2019173283A1 (en) 2018-03-05 2019-09-12 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
US20210393802A1 (en) * 2018-11-14 2021-12-23 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US11707505B2 (en) * 2019-11-15 2023-07-25 King Faisal Specialist Hospital & Research Centre VCP and factor H as viral entry inhibitors
WO2021202836A1 (en) * 2020-04-01 2021-10-07 The Trustees Of The University Of Pennsylvania Factor b inhibitors and uses thereof
BR112022026127A2 (pt) * 2020-06-24 2023-01-17 Bioverativ Therapeutics Inc Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
JP7766325B2 (ja) * 2021-10-13 2025-11-10 学校法人慈恵大学 レンチウイルスベクター、細胞及び細胞製剤
WO2023230171A2 (en) * 2022-05-24 2023-11-30 University Of Pittsburgh - Of Thecommonwealth System Of Highereducation Compositions and methods of treating corneal scarring
EP4584255A1 (en) 2022-09-10 2025-07-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
WO2024206928A1 (en) 2023-03-30 2024-10-03 Pharma Cinq, Llc VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE
AU2024261191A1 (en) 2023-04-27 2025-11-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt of piperidylindole compound and preparation method therefor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5869615A (en) * 1994-01-03 1999-02-09 Washington University Modified complement proteases
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
ES2316446T3 (es) * 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
US20060178348A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID
US20070037183A1 (en) * 2005-03-07 2007-02-15 Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration
AU2006304804B2 (en) * 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation

Also Published As

Publication number Publication date
JP5332064B2 (ja) 2013-11-06
WO2008106644A3 (en) 2008-11-20
EP2134173A2 (en) 2009-12-23
JP2010520224A (ja) 2010-06-10
AU2014203398A1 (en) 2014-07-10
NZ578873A (en) 2012-01-12
WO2008106644A2 (en) 2008-09-04
EP2134173A4 (en) 2010-11-10
IL200368A0 (en) 2010-04-29
AU2008221287A1 (en) 2008-09-04
US20100120665A1 (en) 2010-05-13
CA2678774A1 (en) 2008-09-04
KR20090122465A (ko) 2009-11-30

Similar Documents

Publication Publication Date Title
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
MX345226B (es) Formulaciones de moleculas de union a antigeno de dominio sencillo.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201001883A1 (ru) Мутанты fgf21 и их применение
MX2019005911A (es) Anticuerpos anti_cd137 novedosos y usos de estos.
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
TN2010000169A1 (en) Molecules and methods for modulating complement component
MX2018000470A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22).
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
MY166776A (en) Humanised anti-ctla4 antibodies
MX2009004038A (es) Gel de diclofenaco.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
TN2010000060A1 (en) Proteasome inhibitors
EA201490644A1 (ru) Терапевтические пептиды
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
MX2012006206A (es) Preparaciones combinacion comprendiendo exosomas y corticosteroide.
EA200901249A1 (ru) Ингибиторы связывания протеинкиназ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal